Both in Biotechnology
Fate Therapeutics vs Lineage Cell Therapeutics
Over the past year FATE returned +64.3% and LCTX returned −47.4%; their daily moves had a correlation of 0.27.
FATE +64.3% LCTX −47.4%Growth of $1, one year, split-adjusted
| Metric | FATE | LCTX |
|---|---|---|
| Price | $2.07 | $1.03 |
| Market cap | $248.0M | $260.5M |
| Today | +1.47% | +1.98% |
| 1 month | −9.6% | +9.8% |
| 6 months | −9.6% | −28.0% |
| Year to date | +110.7% | −38.3% |
| 1 year | +64.3% | −47.4% |
| Revenue growth (YoY) | +9.2% | −61.3% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −1448.6% | 138.6% |
| P/E (TTM) | — | — |
| Price / sales | 38.2× | 19.9× |
| Net cash | $153.8M | $50.8M |
| Dividend yield | — | — |
| Volatility (60d) | 56.3% | 52.5% |
| Short % of float | 10.4% | 12.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).